Sonoma Pharmaceuticals, Inc.

Jun 30, 2026

SNOAFDA Updates

Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution

Sonoma Pharmaceuticals has received FDA 510(k) clearance for its Microdacyn Wound Irrigation Solution, allowing for expanded claims and multiple-use applications. The new clearance includes various packaging options, enhancing the product's marketability. CEO Amy Trombly highlighted the strategic importance of this clearance for growth and partnerships in the wound care sector.

Jun 16, 2026

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results

Sonoma Pharmaceuticals reported strong financial results for fiscal year 2026, with a 48% increase in Q4 revenues compared to the previous year. The company also noted a significant improvement in net loss and EBITDA loss. Despite some regional declines in revenue, Sonoma continues to expand its product offerings and distribution networks, focusing on strategic growth and operational efficiency.

Feb 11, 2026

Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results

Sonoma Pharmaceuticals reported a 22% revenue increase for Q3 2026, with a 33% rise for the nine months ending December 31, 2025. The company also noted a decrease in net loss and EBITDAS loss, reflecting improved financial performance. Key developments included successful FDA registration of a manufacturing facility and new product launches, alongside leadership changes to enhance governance.

Jan 29, 2026

Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development

Sonoma Pharmaceuticals has appointed Vanessa Jacoby and Arturo Angel to its Board of Directors and as Senior Vice President, respectively. Jacoby brings extensive financial and biotech experience, while Angel has a strong background in product development. The company also announced the retirement of Dr. Jay Birnbaum, who has been a significant contributor since 2007.

Jan 12, 2026

▼ -6%on this news

Sonoma Pharmaceuticals, Inc. Investor Presentation January 2026 Legal Disclaimers r INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all

Sonoma Pharmaceuticals, Inc. presented an investor communication outlining its capabilities and future outlook, including its patented Microcyn technology. The presentation emphasized the company's global footprint, with over 20 years in the development of stabilized hypochlorous acid products. It also highlighted recent expansions in distribution partnerships, including relationships with Medline Industries. The company boasts robust clinical evidence supporting the efficacy and safety of its products in various healthcare applications.

Sep 29, 2025

Sonoma Pharmaceuticals, Inc. Investor Presentation September 2025 Legal Disclaimers or INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be

Sonoma Pharmaceuticals, Inc. provided an investor presentation detailing its advancements and regulatory achievements as a leader in hypochlorous acid products. The presentation highlights the company's patented Microcyn technology, which is clinically proven for safety and efficacy in various healthcare applications. Despite its successes, Sonoma acknowledges inherent risks associated with regulatory compliance and market penetration challenges. The company is actively expanding its product lines and distribution partnerships, particularly focusing on wound care solutions in the U.S. and internationally.

Apr 28, 2025

▼ -6.9%on this news

Sonoma Pharmaceuticals, Inc. Investor Presentation April 2025 1 Legal Disclaimers or INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be al

Sonoma Pharmaceuticals, Inc. presented an update on its business strategies and product offerings, highlighting its commitment to developing hypochlorous acid (HOCl) products for various healthcare applications. Recent partnerships and a strong regulatory portfolio were emphasized, alongside the effectiveness and safety of its Microcyn technology. Despite the optimistic outlook, the company also acknowledged potential market risks and challenges in achieving regulatory approvals. The focus remains on expanding its reach in the global healthcare market, with ongoing product innovations and collaborations.

Apr 7, 2025

▼ -5.4%on this news

Sonoma Pharmaceuticals, Inc. Investor Presentation April 2025 Legal Disclaimers or INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all

Sonoma Pharmaceuticals, Inc. recently presented an investor communication outlining its business operations and future outlook. The company's products leverage patented Microcyn technology, showing efficacy in various medical applications, including wound and dermatological care. However, the presentation also highlighted inherent risks associated with forward-looking statements, such as potential regulatory hurdles and market competition. Additionally, Sonoma emphasized its extensive regulatory portfolio and partnerships that support its global market presence.

Oct 22, 2024

Sonoma Pharmaceuticals, Inc. Investor Presentation October 2024 Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all -

Sonoma Pharmaceuticals, Inc. recently highlighted its ongoing developments in its investor presentation for October 2024. The company continues to make strides in the hypochlorous acid market, supported by an extensive regulatory portfolio and a diverse application of their products. New distribution agreements have been established, particularly with Medline Industries for U.S. and Canadian markets. However, Sonoma acknowledges inherent risks associated with forward-looking statements, including regulatory developments and market competition, which may influence their financial performance.

Aug 28, 2024

▼ -25%on this news· ran to -35% by day 3

Sonoma Pharmaceuticals Announces 1-for-20 Reverse Split of Outstanding Common Stock

Sonoma Pharmaceuticals announced a 1-for-20 reverse stock split effective August 29, 2024. The decision, backed by stockholder approval, aims to bolster the company's stock price for continued compliance with Nasdaq's listing requirements. Notably, each twenty shares will convert into one share, reducing the total from approximately 20 million to 1 million shares outstanding. The split underscores potential financial challenges, as maintaining the Nasdaq listing could be pivotal for the company's investment credibility.

Apr 9, 2024

▲ +6.3%on this news· ran to +19% by day 3

Sonoma Pharmaceuticals, Inc. Investor Presentation

Sonoma Pharmaceuticals, Inc. presented key insights into its operations and technological advancements in its recent investor presentation. The company specializes in stabilized hypochlorous acid products, which are utilized across various healthcare sectors, including dermatology, wound care, and disinfectants. Despite demonstrating strong performance and safety records, potential risks related to regulatory developments and market competition were acknowledged, indicating that future growth may be uncertain. Sonoma's extensive global distribution network and proprietary technology position it well in the healthcare market.

Apr 2, 2024

▼ -5.4%on this news

Sonoma Pharmaceuticals, Inc. Investor Presentation April 2024 Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - i

Sonoma Pharmaceuticals, Inc. held an investor presentation in April 2024 to discuss its advancements and offerings in healthcare products featuring stabilized hypochlorous acid (HOCl). The presentation emphasized the company's extensive regulatory accomplishments, including multiple FDA clearances and its global reach, distributing products in over 55 countries. The firm also highlighted the safety and efficacy of its products, which cater to a variety of medical fields such as dermatology, wound care, and animal health. Despite the optimistic outlook presented, no specific risks were identified in this communication.

Jan 10, 2024

▲ +13%on this news· ran to +26% by day 1

Sonoma Pharmaceuticals, Inc. Investor Presentation January 2024 Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all -

Sonoma Pharmaceuticals, Inc. provided an investor presentation highlighting its advancements in hypochlorous acid products. The presentation underscores the company’s leadership in wound care and dermatological solutions with a proven safety profile. However, it also outlines several risks associated with future performance, including regulatory hurdles and market penetration challenges. Sonoma operates a state-of-the-art facility in Mexico, emphasizing its commitment to innovation and an extensive global partner network.

Oct 11, 2023

Sonoma Pharmaceuticals, Inc. Investor Presentation October 2023 Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all -

Sonoma Pharmaceuticals, Inc. has presented an investor update outlining its progress and strategic direction. The company focuses on developing stabilized hypochlorous acid products shown to have therapeutic benefits across various medical and consumer applications. With over 20 years in the industry, Sonoma has established a significant footprint with numerous patents and regulatory approvals. However, challenges related to market competition and the uncertainties surrounding future performance were also highlighted in the presentation.

May 10, 2023

Sonoma Pharmaceuticals, Inc. May 2023 1 Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - inclusive. T he data co

Sonoma Pharmaceuticals, Inc. provided an investor presentation that outlined its diverse healthcare portfolio and its advancements in stabilized hypochlorous acid (HOCl) products. The company emphasized its history of FDA clearances and the potential to expand into lucrative markets such as dermatology and wound care. While Sonoma has established a robust international distribution network, it acknowledged various risks including regulatory uncertainties and financial constraints. The presentation also highlighted recent partnerships to enhance sales and product distribution across multiple regions.

Jan 6, 2023

Sonoma Pharmaceuticals, Inc. January 202 3 Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - inclusive. T he data

Sonoma Pharmaceuticals, Inc. has presented its latest developments and market opportunities in a recent investor presentation. Notably, the company launched two new dermatological products in January 2023 and is actively expanding its product distribution both domestically and internationally. While the presentation highlights strong clinical efficacy for its products, it acknowledges inherent risks related to regulatory approvals and market competition. The company aims to capitalize on growing markets, especially in the healthcare sector focused on non-toxic skin care solutions.

Jan 6, 2022

Sonoma Pharmaceuticals, Inc. NASDAQ: SNOA January 2022 1 Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - inclus

Sonoma Pharmaceuticals, Inc. NASDAQ: SNOA January 2022 Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - inclusive. T he data contained herein is derived from various inter

Mar 4, 2021

Sonoma Pharmaceuticals, Inc. NASDAQ: SNOA March 2021 Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - inclusive.

Sonoma Pharmaceuticals, Inc. NASDAQ: SNOA March 2021 Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - inclusive. T he data contained herein is derived from various interna

Feb 9, 2021

Sonoma Hills Farm Announces Farmer’s Reserve Collection: Limited Edition, Premium Strains Packaged in All-in-One Flower & Glass Pipe Combo

Petaluma, CA, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Sonoma Hills Farm, a premium craft cannabis farm and culinary garden located in Sonoma County, has announced its newest product offering: the Farmer’s Reserve Collection. Sourced from the farm’s most unique genetics, these limited

Feb 2, 2021